Q4 2021 13F Holders as of 12/31/2021
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
108M
-
Number of holders
-
356
-
Total 13F shares, excl. options
-
63.9M
-
Shares change
-
+1.82M
-
Total reported value, excl. options
-
$7.56B
-
Value change
-
+$200M
-
Put/Call ratio
-
1.45
-
Number of buys
-
158
-
Number of sells
-
-165
-
Price
-
$118.24
Significant Holders of Intellia Therapeutics, Inc. - Common Stock, par value $0.0001 per share (NTLA) as of Q4 2021
437 filings reported holding NTLA - Intellia Therapeutics, Inc. - Common Stock, par value $0.0001 per share as of Q4 2021.
Intellia Therapeutics, Inc. - Common Stock, par value $0.0001 per share (NTLA) has 356 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 63.9M shares
of 108M outstanding shares and own 59.24% of the company stock.
Largest 10 shareholders include ARK Investment Management LLC (7.92M shares), VANGUARD GROUP INC (6.44M shares), BlackRock Inc. (5.62M shares), FMR LLC (3.88M shares), Sumitomo Mitsui Trust Holdings, Inc. (2.75M shares), Nikko Asset Management Americas, Inc. (2.75M shares), PRICE T ROWE ASSOCIATES INC /MD/ (2.1M shares), STATE STREET CORP (1.84M shares), VIKING GLOBAL INVESTORS LP (1.58M shares), and MORGAN STANLEY (1.52M shares).
This table shows the top 356 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.